Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

doi:10.3201/eid1411.080337

Comparative Study

. 2008 Nov;14(11):1756-8.

doi: 10.3201/eid1411.080337.

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Marya D Zilberberg¹, Andrew F Shorr, Marin H Kollef

Affiliations

PMID: 18976563
PMCID: PMC2630735
DOI: 10.3201/eid1411.080337

Comparative Study

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Marya D Zilberberg et al. Emerg Infect Dis. 2008 Nov.

. 2008 Nov;14(11):1756-8.

doi: 10.3201/eid1411.080337.

Authors

Marya D Zilberberg¹, Andrew F Shorr, Marin H Kollef

Affiliation

¹ EviMed Research Group, LLC, Goshen, Massachussetts 01032, USA. marya@evimedgroup.org

PMID: 18976563
PMCID: PMC2630735
DOI: 10.3201/eid1411.080337

Abstract

From 2000 through 2005, hospitalizations with resistant infections (methicillin-resistant Staphylococcus aureus, Clostridium difficile-associated disease, vancomycin-resistant enterococcus, Pseudomonas aeruginosa, and Candida infection) nearly doubled, from 499,702 to 947,393. Regional variations noted in the aggregate and by individual infection may help clarify modifiable risk factors driving these infections.

PubMed Disclaimer

Figures

**Figure**
Population incidence of component resistant infections in the United States, by census region, 2000–2005. A) *Clostridium difficile–*associated disease; B) methicillin-resistant *Staphylococcus aureus*; C) vancomycin-resistant enterococcus; D) *Pseudomonas aeruginosa*; E) *Candida* spp.

See this image and copyright information in PMC

Cited by

Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004-2013.
Zilberberg MD, Harrington R, Spalding JR, Shorr AF. Zilberberg MD, et al. BMC Public Health. 2019 May 17;19(1):591. doi: 10.1186/s12889-019-6932-9. BMC Public Health. 2019. PMID: 31101036 Free PMC article.
Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection.
Weingarden AR, Chen C, Zhang N, Graiziger CT, Dosa PI, Steer CJ, Shaughnessy MK, Johnson JR, Sadowsky MJ, Khoruts A. Weingarden AR, et al. J Clin Gastroenterol. 2016 Sep;50(8):624-30. doi: 10.1097/MCG.0000000000000427. J Clin Gastroenterol. 2016. PMID: 26485102 Free PMC article.
IL-17-producing γδ T cells protect against Clostridium difficile infection.
Chen YS, Chen IB, Pham G, Shao TY, Bangar H, Way SS, Haslam DB. Chen YS, et al. J Clin Invest. 2020 May 1;130(5):2377-2390. doi: 10.1172/JCI127242. J Clin Invest. 2020. PMID: 31990686 Free PMC article.
Colonization With Vancomycin-Resistant Enterococci and Risk for Bloodstream Infection Among Patients With Malignancy: A Systematic Review and Meta-Analysis.
Alevizakos M, Gaitanidis A, Nasioudis D, Tori K, Flokas ME, Mylonakis E. Alevizakos M, et al. Open Forum Infect Dis. 2016 Dec 7;4(1):ofw246. doi: 10.1093/ofid/ofw246. eCollection 2017 Winter. Open Forum Infect Dis. 2016. PMID: 28480243 Free PMC article.
Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.
Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. Zilberberg MD, et al. BMC Pulm Med. 2010 Aug 26;10:45. doi: 10.1186/1471-2466-10-45. BMC Pulm Med. 2010. PMID: 20796312 Free PMC article. Review.

See all "Cited by" articles

References

1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6. - PMC - PubMed
1. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31. 10.3201/eid1411.080337 - DOI - PMC - PubMed
1. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788–94. 10.1093/jac/dkm258 - DOI - PubMed
1. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35:300–7. 10.1007/s15010-007-6113-0 - DOI - PubMed
1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–74. 10.1056/NEJMoa055356 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information

[1] Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6. - PMC - PubMed

[2] Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6. - PMC - PubMed

[3] Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31. 10.3201/eid1411.080337 - DOI - PMC - PubMed

[4] Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31. 10.3201/eid1411.080337 - DOI - PMC - PubMed

[5] Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788–94. 10.1093/jac/dkm258 - DOI - PubMed

[6] Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788–94. 10.1093/jac/dkm258 - DOI - PubMed

[7] Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35:300–7. 10.1007/s15010-007-6113-0 - DOI - PubMed

[8] Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35:300–7. 10.1007/s15010-007-6113-0 - DOI - PubMed

[9] Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–74. 10.1056/NEJMoa055356 - DOI - PubMed

[10] Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–74. 10.1056/NEJMoa055356 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Affiliation

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Authors

Affiliation

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical